Pharming gets final approval for flagship drug launch in Europe.

(ADPnews) - Oct 28, 2010 - Dutch biotechnology firm Pharming Group NV (AMS:PHARM) said today its flagship drug Ruconest was granted a definitive marketing approval by the European Commission.

Pharming will receive a EUR 5 million (USD 6.9m) milestone payment from Swedish Orphan Biovitrum AB (STO:BVT), its marketing and distribution partner, the Dutch firm said.

…